DiscGenics recently participated in its second Fireside Chat hosted by FORCE Family Office Founder and CEO, Steven Saltzstein. During this discussion, our novel, investigational Discogenic Cell therapy, IDCT, was explored as a promising breakthrough in the treatment of degenerative disc disease.

Featured Panelists:

Dr. Kevin Foley: A practicing Neurosurgeon and active entrepreneur who has created many of the surgical devices that have revolutionized minimally invasive spine surgery. Dr. Foley is the Chairman of Semmes Murphey Clinic, tenured Professor of Neurosurgery, Orthopaedic Surgery, & Biomedical Engineering at the University of Tennessee, and serves as the Chief Medical Officer and board member at DiscGenics.

Matthew O'Brien: As Managing Director and Senior Research Analyst at Piper Sandler, Matt brings decades of investment banking experience and in-depth knowledge of the medical technology and devices industry.

Flagg Flanagan: As the CEO & Chairman of DiscGenics, Flagg is an entrepreneur, executive, and advisor with over 30 years of experience in the surgical device and biopharmaceutical fields.

Webinar Highlights:

Learn about the cutting-edge Injectable Discogenic Cell Therapy (IDCT) and its potential to transform the treatment of degenerative disc disease.
Discover the results of a recent FDA-approved clinical trial of IDCT, which included improvements in back pain, function, and quality of life, as well as increased disc volume, suggesting a regenerative effect.
Explore the market opportunity for DiscGenics’ platform technology in other musculoskeletal indications.

Disclaimer: IDCT (rebonuputemcel) is an investigational product that is under development by DiscGenics and has not been approved by the FDA or any other regulatory agency for human use.